Ernesto Scibona

Ernesto Scibona

Auto-generated profile, based on publicly available information

Ernesto Scibona

Department of Chemistry and Applied Biosciences, Institute for Chemical and Bioengineering, ETH Zurich, Vladimir-Prelog-Weg 1, 8093 Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
AAAndrea Aloia
Andrea Aloia
DMDaniela Müllhaupt
Daniela Müllhaupt
CCChristophe D. Chabbert
Christophe D. Chabbert
TETanja Eberhart
Tanja Eberhart
SFStefanie Flückiger-Mangual
Stefanie Flückiger-Mangual
WKWerner Kovacs
Werner Kovacs
Purpose: Treatment of BRAFV600E-mutant melanomas with MAPK inhibitors (MAPKi) results in significant tumor regression, but acquired resistance is pervasive. To understand nonmutational mechanisms underlying the adaptation to MAPKi and to identify novel vulnerabilities of melanomas treated with MAPKi, we focused on the initial response phase during treatment with MAPKi. Experimental Design: By screening proteins expressed on the cell surface of melanoma cells, we identified the fatty acid transporter CD36 as the most consistently upregulated protein upon short-term treatment with MAPKi. We further investigated the effects of MAPKi on fatty acid metabolism using in vitro and in vivo models and analyzing patients' pre- and on-treatment tumor specimens. Results: Melanoma cells treated with MAPKi displayed increased levels of CD36 and of PPARα-mediated and carnitine palmitoyltransferase 1A (CPT1A)-dependent fatty acid oxidation (FAO). While CD36 is a useful marker of melanoma cells during adaptation and drug-tolerant phases, the upregulation of CD36 is not functionally involved in FAO changes that characterize MAPKi-treated cells. Increased FAO is required for BRAFV600E-mutant melanoma cells to survive under the MAPKi-induced metabolic stress prior to acquiring drug resistance. The upfront and concomitant inhibition of FAO, glycolysis, and MAPK synergistically inhibits tumor cell growth in vitro and in vivo. Conclusions: Thus, we identified a clinically relevant therapeutic approach that has the potential to improve initial responses and to delay acquired drug resistance of BRAFV600E-mutant melanoma.

14 April 2017 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
DKDaniel J. Karst
Daniel J. Karst
ESErnesto Scibona
Ernesto Scibona
ESElisa Serra
Elisa Serra
JBJean‐Marc Bielser
Jean‐Marc Bielser
JSJonathan Souquet
Jonathan Souquet
TVThomas K. Villiger
Thomas K. Villiger

6 June 2016 in Biotechnology Progress
Verified
Journal Article
Closed access
PDF file
TVThomas K. Villiger
Thomas K. Villiger
ESErnesto Scibona
Ernesto Scibona
MSMatthieu Stettler
Matthieu Stettler
HBHervé Broly
Hervé Broly
Massimo MorbidelliMassimo Morbidelli
Massimo Morbidelli
MSMiroslav Soos
Miroslav Soos

1 November 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
IAIlaria Arigoni-Affolter
Ilaria Arigoni-Affolter
ESErnesto Scibona
Ernesto Scibona
CLChia-Wei Lin
Chia-Wei Lin
DBDavid Brühlmann
David Brühlmann
JSJonathan Souquet
Jonathan Souquet
MAMarkus Aebi
Markus Aebi
Kinetic analysis of intracellular intermediates affords a mathematical model for N-glycoprotein processing and secretion.

5 July 2017 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MLMarie‐Estelle Losfeld
Marie‐Estelle Losfeld
ESErnesto Scibona
Ernesto Scibona
CLChia‐Wei Lin
Chia‐Wei Lin
TVThomas K. Villiger
Thomas K. Villiger
RGRobert Gauss
Robert Gauss
MAMarkus Aebi
Markus Aebi
To study how the interaction between N ‐linked glycans and the surrounding amino acids influences oligosaccharide processing, we used protein disulfide isomerase (PDI), a glycoprotein bearing 5 N ‐glycosylation sites, as a model system and expressed it transiently in a Chinese hamster ovary (CHO)‐S cell line. PDI was produced as both secreted Sec‐PDI and endoplasmic reticulum‐retained glycoprotein (ER)‐PDI, to study glycan processing by ER and Golgi resident enzymes. Quantitative site‐specific glycosylation profiles were obtained, and flux analysis enabled modeling site‐specific glycan processing. By altering the primary sequence of PDI, we changed the glycan/protein interaction and thus the site‐specific glycoprofile because of the improved enzymatic fluxes at enzymatic bottlenecks. Our results highlight the importance of direct interactions between N ‐glycans and surface‐exposed amino acids of glycoproteins on processing in the ER and the Golgi and the possibility of changing a site‐specific N ‐glycan profile by modulating such interactions and thus the associated enzymatic fluxes. Altering the primary protein sequence can therefore be used to glycoengineer recombinant proteins.—Losfeld, M.‐E., Scibona, E., Lin, C.‐W., Villiger, T. K., Gauss, R., Morbidelli, M., Aebi, M. Influence of protein/glycan interaction on site‐specific glycan heterogeneity. FASEB J. 31, 4623‐4635 (2017). www.fasebj.org

1 December 2019 in Biotechnology Advances
Verified
Journal Article
Closed access
ESErnesto Scibona
Ernesto Scibona
Massimo MorbidelliMassimo Morbidelli
Massimo Morbidelli